-
公开(公告)号：US20200270266A1
公开(公告)日：2020-08-27
申请号：US16871532
申请日：2020-05-11
发明人： Ippei SATO , Takashi KAMIKUBO , Masanori MIURA , Yuji MATSUSHIMA , Hiroaki TANAKA , Yasuhiro SHIINA , Susumu YAMAKI , Tomoyuki SAITO , Hiroshi KIYOHARA , Munemichi OHE , Kayoko MIHARA , Bradley Paul MORGAN , Fady MALIK , Scott Emile COLLIBEE , Luke ASHCRAFT , Pu-Ping LU , Jeffrey Michael WARRINGTON , Marc GARARD
IPC分类号： C07D491/20 , C07D491/107 , C07D217/24 , C07D471/04 , C07D217/26 , C07D471/10 , A61P21/00
摘要： Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.
-
公开(公告)号：US20140179695A1
公开(公告)日：2014-06-26
申请号：US14192667
申请日：2014-02-27
发明人： Ryosuke MUNAKATA , Makoto INOUE , Hiroaki TOMINAGA , Shingo YAMASAKI , Yasuhiro SHIINA , Kiyohiro SAMIZU , Hisao HAMAGUCHI , Lin HONG
IPC分类号： C07D498/20 , C07D498/10 , C07D519/00
CPC分类号： C07D413/14 , C07D263/52 , C07D498/10 , C07D498/20 , C07D519/00
摘要： The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases or conditions associated with and/or mediated by β-secretase activity, hydrolysis of a β-secretase site of a β-amyloid precursor protein, and/or β-amyloid protein accumulation, including a pharmaceutical composition for preventing or treating diseases including, but not limited to, Glaucoma, MCI (Mild cognitive impairment) or Alzheimer's disease, especially, Alzheimer's disease.
摘要翻译： 本发明提供了一种化合物，其可用作药物组合物的活性成分，特别是用于预防或治疗与分泌酶活性相关和/或介导的疾病或病症的药物组合物， 包括淀粉样蛋白前体蛋白的分泌酶位点和/或β-淀粉样蛋白积聚，包括用于预防或治疗疾病的药物组合物，包括但不限于青光眼，MCI（轻度认知障碍）或阿尔茨海默病，特别是 ， 阿尔茨海默氏病。
-
公开(公告)号：US20230125280A1
公开(公告)日：2023-04-27
申请号：US17944060
申请日：2022-09-13
发明人： Ippei SATO , Takashi KAMIKUBO , Masanori MIURA , Yuji MATSUSHIMA , Hiroaki TANAKA , Yasuhiro SHIINA , Susumu YAMAKI , Tomoyuki SAITO , Hiroshi KIYOHARA , Munemichi OHE , Kayoko MIHARA , Bradley Paul MORGAN , Fady MALIK , Scott Emile COLLIBEE , Luke ASHCRAFT , Pu-Ping LU , Jeffrey Michael WARRINGTON , Marc GARARD
IPC分类号： C07D491/20 , C07D491/107 , C07D217/24 , C07D471/04 , C07D217/26 , C07D471/10 , A61P21/00
摘要： Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.
-
-
搜索结果
3 条记录 (耗时 0.018 秒)
